Oculis Holding AG (Oculis Holding AG) Notes Receivable : $0.00 Mil (As of Mar. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Oculis Holding AG Notes Receivable?

Oculis Holding AG's Notes Receivable for the quarter that ended in Mar. 2024 was $0.00 Mil.

Oculis Holding AG Notes Receivable Historical Data

The historical data trend for Oculis Holding AG's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oculis Holding AG Notes Receivable Chart

Oculis Holding AG Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Notes Receivable

Oculis Holding AG Quarterly Data
	Dec20	Jun21	Sep21	Dec21	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Notes Receivable	Get a 7-Day Free Trial							-	-	-	-	-

Oculis Holding AG Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.

Oculis Holding AG Notes Receivable Related Terms

Thank you for viewing the detailed overview of Oculis Holding AG's Notes Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.

Oculis Holding AG (Oculis Holding AG) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oculis Holding AG (NAS:OCS) » Definitions » Notes Receivable

Comparable Companies

Traded in Other Exchanges

OCS:Iceland

Address

Bahnhofstrasse 7, Zug, CHE, 6300

Website

https://www.oculis.com

Oculis Holding AG is a global biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis.